GANX — Gain Therapeutics Inc

Gain Therapeutics Inc (GANX) is a biotechnology company listed on NASDAQ. It is led by Gene Mack M.B.A., based in 4800 Montgomery Lane, Bethesda, MD, United States, 20814, with about 23 employees. Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.

Net income was -$15.6M. GANX currently screens at market cap $53.0M.

Use this GANX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the GANX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the GANX SEC filings page. Lician reads the product cache first so this HTML stays unique to Gain Therapeutics Inc even when a live quote feed is slow.